Thursday, December 7, 2023, 7:15 PM – 8:45 PM CT (8:15 PM – 9:45 PM ET) | San Antonio, Texas
Beyond the Guidelines: Clinical Investigator Perspectives on the Management of HER2-Low Breast Cancer
Part 3 of a 3-Part CME Satellite Symposium Series in Partnership with the 2023 San Antonio Breast Cancer Symposium®
Event Details
San Antonio Marriott Rivercenter
101 Bowie St
San Antonio, Texas
Hotel Phone: (210) 223-1000
Program Schedule — Central Time
7:00 PM – 7:15 PM — Registration
7:15 PM – 8:45 PM — Dinner Meeting
Meeting Room
Grand Ballroom G-M (Third Floor)
This event will also be webcast live.
Please see Registration tab for details.
Aditya Bardia, MD, MPH
Director
Breast Cancer Research Program
Associate Professor
Harvard Medical School
Attending Physician
Massachusetts General Hospital
Boston, Massachusetts
Lisa A Carey, MD, ScM, FASCO
L Richardson and Marilyn Jacobs Preyer Distinguished Professor for Breast Cancer Research
Deputy Director for Clinical Sciences
Lineberger Comprehensive Cancer Center
University of North Carolina
Chapel Hill, North Carolina
Shanu Modi, MD
Member and Attending
Breast Medicine Service
Memorial Sloan Kettering Cancer Center
Professor of Medicine
Weill Cornell Medical College
New York, New York
Professor Peter Schmid, FRCP, MD, PhD
Lead, Centre of Experimental
Cancer Medicine
Barts Cancer Institute
London, United Kingdom
Moderator
Neil Love, MD
Research To Practice
Miami, Florida
This symposium is sponsored by Research To Practice and supported by grants from AstraZeneca Pharmaceuticals LP and Daiichi Sankyo Inc. This is not an official program of the San Antonio Breast Cancer Symposium®.
Agenda
7:00 PM – 7:15 PM — Registration
7:15 PM – 8:45 PM — Dinner Meeting
MODULE 1: Optimal Approaches to HER2 Testing for the Identification of HER2-Low Breast Cancer — Dr Carey
- Historical guidelines for routine HER2 assessment in patients with newly diagnosed and recurrent breast cancer; thresholds for HER2 negativity and positivity
- Definition, incidence and clinicopathologic and molecular characteristics of HER2-low breast cancer
- Appropriate testing strategies to identify patients with HER2-low breast cancer
- Accuracy of testing for HER2 in centralized versus regional laboratories; implications for identifying HER2-low disease in community practice
- Novel complementary HER2-assessment methodologies under investigation in breast cancer; sensitivity of these strategies compared to conventional immunohistochemistry (IHC) or fluorescence in situ hybridization in predicting response to anti-HER2 therapy
MODULE 2: Available Data with and Current Role of HER2-Targeted Therapy for HER2-Low Disease — Dr Modi
- Historical management approaches for HR-positive or HR-negative, HER2-low metastatic breast cancer (mBC); antitumor efficacy observed with established anti-HER2 agents, such as trastuzumab, pertuzumab and T-DM1
- Rationale for the clinical activity observed with trastuzumab deruxtecan (T-DXd) in patients with HER2-low breast cancer
- Design, eligibility criteria and key endpoints of the Phase III DESTINY-Breast04 study evaluating T-DXd versus chemotherapy for patients with previously treated HER2-low advanced breast cancer
- Key efficacy outcomes with T-DXd in the DESTINY-Breast04 trial; effects of IHC status, HR status and prior therapy
- FDA approval of T-DXd for patients with previously treated HER2-low advanced breast cancer; appropriate integration of T-DXd in relation to traditional therapies for HR-positive and HR-negative disease
MODULE 3: Identification and Management of Toxicities with T-DXd — Prof Schmid
- Spectrum, incidence and severity of common (eg, gastrointestinal toxicities, myelosuppression) and more serious (eg, interstitial lung disease [ILD]/pneumonitis) treatment-emergent adverse events observed with T-DXd in the DESTINY-Breast04 trial
- Recommendations for monitoring and immediate reporting of symptoms of ILD/pneumonitis with T-DXd
- Strategies to manage T-DXd-associated ILD/pneumonitis; indications for restarting T-DXd after resolution of symptoms
- Appropriate monitoring of complete blood counts and left ventricular ejection fraction during therapy with T-DXd
- Recommended algorithms for mitigating and managing cytopenias, gastrointestinal side effects and other complications with T-DXd
MODULE 4: Future Directions in the Management of HER2-Low Breast Cancer — Dr Bardia
- Definition and incidence of HER2 ultra-low breast cancer; biological rationale for the activity of T-DXd in these patients
- Available data from the Phase II DAISY trial with T-DXd for patients with HER2 IHC 0 mBC
- Design, eligibility criteria and key endpoints of the Phase III DESTINY-Breast06 trial assessing T-DXd versus chemotherapy for ER-positive, HER2-low and ER-positive, HER2 ultra-low mBC progressing after CDK4/6 inhibitor therapy; anticipated date of completion
- Rationale for combining T-DXd with other systemic therapies, such as immunotherapy, endocrine therapy, targeted therapy or chemotherapy, for patients with HER2-low breast cancer; early data and ongoing research with combination approaches
- Early clinical research findings with and ongoing evaluation of T-DXd for HER2-low localized breast cancer
- Mechanisms of action of, published data with and ongoing investigation of other novel HER2-targeted agents under investigation for HER2-low breast cancer (trastuzumab duocarmazine, disitamab vedotin)
- Implications for the management of HER2-low disease of recently presented findings from the Phase III TROPION-Breast01 study of datopotamab deruxtecan versus chemotherapy for pretreated ER-positive mBC
CE Information
Target Audience
This activity is intended for medical oncologists, breast surgeons, radiation oncologists and other healthcare professionals involved in the diagnosis and treatment of breast cancer.
Learning Objectives
At the conclusion of this activity, participants should be able to
- Appreciate the incidence, pathological and molecular characteristics and clinical relevance of HER2-low breast cancer, and understand currently available management approaches for this disease subset.
- Recognize the current definition of HER2-low breast cancer, and be aware of the potential dynamic evolution of HER2 expression throughout the disease course.
- Enhance interdisciplinary communication among colleagues regarding HER2 testing requirements and optimal reporting of results in order to more effectively identify patients with HER2-low breast cancer.
- Appraise available clinical research establishing the safety and efficacy of trastuzumab deruxtecan for patients with HR-positive or HR-negative, HER2-low metastatic breast cancer, and formulate a plan to optimally incorporate this agent into treatment algorithms.
- Recognize the spectrum, frequency and severity of treatment-emergent adverse events associated with trastuzumab deruxtecan, and develop strategies to monitor for, prevent and manage these complications.
- Recall the design of ongoing clinical trials evaluating novel therapeutic strategies for HER2-low breast cancer, and appropriately counsel patients about availability and participation.
CME Credit Form
A CME credit link will be given to each participant at the conclusion of the activity.
Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
FACULTY — Dr Carey has no relevant conflicts of interest to disclose. The following faculty reported relevant conflicts of interest, which have been mitigated through a conflict of interest mitigation process:
Dr Bardia — Consulting Agreements and Contracted Research: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Lilly, Menarini Group, Merck, Novartis, Pfizer Inc, Radius Health Inc, Sanofi. Dr Modi — Advisory Committee and Consulting Agreements: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Seagen Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Seagen Inc. Prof Schmid — Consulting Agreements: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Celgene Corporation, Daiichi Sankyo Inc, Eisai Inc, Gilead Sciences Inc, Lilly, Merck, Novartis, Pfizer Inc, Puma Biotechnology Inc, Roche Laboratories Inc; Contracted Research: Astellas, AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, Medivation Inc, a Pfizer Company, Novartis, OncoGenex Pharmaceuticals Inc, Roche Laboratories Inc.
MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI Biopharma, a Sobi company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Legend Biotech, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.
RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP and Daiichi Sankyo Inc.
Location
San Antonio Marriott Rivercenter
101 Bowie St
San Antonio, TX 78205
Hotel Phone: (210) 223-1000
Meeting Room
Grand Ballroom G-M (Third Floor)
Directions
The Marriott Rivercenter hotel is conveniently located within walking distance (1.5 blocks) of the Henry B González Convention Center, where the 2023 San Antonio Breast Cancer Symposium is taking place.
Registration
There is no fee to participate in this hybrid event. In order to attend the in-person symposium in San Antonio, you must also be registered to attend the 2023 San Antonio Breast Cancer Symposium®. Preregistration (below) is required as seating is limited for this program.
Thank you for your interest in our CME program. At this time online preregistration is closed for this event. SEATS ARE STILL AVAILABLE FOR THIS SESSION. Our Onsite Registration Desk will be open at 6:45 PM CT on Thursday,, December 7th. If you are interested in attending, please visit our registration desk located outside the Grand Ballroom G-M (Third Floor) of the Marriott Rivercenter hotel (101 Bowie St) within walking distance of the Henry B Gonzalez Convention Center. We will accommodate as many onsite attendees as possible. Seating will be prioritized for clinicians in practice.
If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com or call (800) 233-6153.
NOTICE: Registration for this event is independent of registration for the SABCS Conference.
Please note, we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions.
REGISTRATION FOR WEBCAST »Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.
Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.
If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153.